Cat. No.: HY-12053

Copy Link Print Information

Vinorelbine

Name: Vinorelbine
Brand: MedChemExpress
SKU: HY-12053
Availability: PreOrder

(Synonyms: KW-2307 base)

24 Cited Publications

Customer Review

Based on 24 publication(s) in Google Scholar

Vinorelbine is an anti-mitotic agent which inhibits the proliferation of Hela cells with IC₅₀ of 1.25 nM.

The free form of the compound is prone to instability, it is advisable to consider the stable salt form (Vinorelbine ditartrate) that retains the same biological activity.

For research use only. We do not sell to patients.

CAS No.: 71486-22-1
Formula: C₄₅H₅₄N₄O₈
Molecular Weight:778.93

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (301 KB)

Vinorelbine Chemical Structure

CAS No.: 71486-22-1

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Other In-stock Forms of Vinorelbine

Vinorelbine ditartrate

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (24)
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Vinorelbine is an anti-mitotic agent which inhibits the proliferation of Hela cells with IC₅₀ of 1.25 nM.

Cellular Effect

Cell Line	Type	Value	Description	References
A2058	GI₅₀	0.002 μM Compound: Vinorelbine	Antiproliferative activity against human A2058 cells assessed as growth inhibition measured for 48 hrs by MTT assay Antiproliferative activity against human A2058 cells assessed as growth inhibition measured for 48 hrs by MTT assay	[PMID: 38833507]
A-375	IC₅₀	0.6 nM Compound: VN	Antiproliferative activity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
A-431	IC₅₀	60 nM Compound: Vinorelbine	Antiproliferative activity against human A431 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human A431 cells after 72 hrs by sulforhodamine B assay	[PMID: 21480626]
A549	IC₅₀	0.049 μM Compound: 1e, AVLB	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 17544278]
A549	IC₅₀	36.9 nM Compound: 1a	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 18771244]
A549	IC₅₀	0.03 μM Compound: 1e	Cytotoxicity against human A549 cells by sulforhodamine B assay Cytotoxicity against human A549 cells by sulforhodamine B assay	[PMID: 19499938]
A549	IC₅₀	26.1 μM Compound: vinorelbine	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 20462230]
A549	IC₅₀	26.1 μmol Compound: vinorelbine	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 20462230]
A549	IC₅₀	64.6 nM Compound: Vinorelbine	Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 21480626]
A549	IC₅₀	10 nM Compound: 1d	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 22525316]
A549	IC₅₀	9 nM Compound: 1d, NVB	Cytotoxicity against human A549 cells after 24 to 72 hrs by MTT assay Cytotoxicity against human A549 cells after 24 to 72 hrs by MTT assay	[PMID: 23107481]
A549	IC₅₀	0.6 μM Compound: Vinorelbine	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
BT-474	IC₅₀	0.3 nM Compound: VN	Antiproliferative activity against human BT-474 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human BT-474 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
CAKI-1	IC₅₀	0.3 nM Compound: VN	Antiproliferative activity against human CAKI-1 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human CAKI-1 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
HCC1937	IC₅₀	>10 μM Compound: Vinorelbine	Antiproliferative activity against exponentially growing adherent human HCC1937 cells assessed as inhibition of cell proliferation after 72 hrs by luminescence detection based ATPlite assay Antiproliferative activity against exponentially growing adherent human HCC1937 cells assessed as inhibition of cell proliferation after 72 hrs by luminescence detection based ATPlite assay	[PMID: 25872984]
HCC44	GI₅₀	0.005 μM Compound: Vinorelbine	Antiproliferative activity against human HCC44 cells assessed as growth inhibition measured for 48 hrs by MTT assay Antiproliferative activity against human HCC44 cells assessed as growth inhibition measured for 48 hrs by MTT assay	[PMID: 38833507]
HCT-116	IC₅₀	75 nM Compound: 22	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by phosphatase assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by phosphatase assay	[PMID: 23252481]
HCT-116	IC₅₀	35 nM Compound: 7, VLN	Cytotoxicity against human HCT116 cells after 72 hrs by resazurin assay Cytotoxicity against human HCT116 cells after 72 hrs by resazurin assay	[PMID: 23822556]
HCT-116	IC₅₀	35 nM Compound: 4, VLN	Antiproliferative activity against human HCT116 cells after 72 hrs Antiproliferative activity against human HCT116 cells after 72 hrs	[PMID: 24871162]
HCT-116	IC₅₀	0.015 μM Compound: Vinorelbine	Cytotoxicity against human HCT116 cells after 72 hrs by resazurin-based fluorimetric assay Cytotoxicity against human HCT116 cells after 72 hrs by resazurin-based fluorimetric assay	[PMID: 24901800]
HCT-116	IC₅₀	15 nM Compound: 3, VLN	Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs	[PMID: 25804719]
HCT-116	IC₅₀	0.0149 μM Compound: Vinorelbine	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32473523]
HCT-116/VM46	IC₅₀	600 nM Compound: 22	Cytotoxicity against human vinblastine-resistant HCT116/VM46 cells assessed as growth inhibition after 72 hrs by phosphatase assay Cytotoxicity against human vinblastine-resistant HCT116/VM46 cells assessed as growth inhibition after 72 hrs by phosphatase assay	[PMID: 23252481]
HEK293	GI₅₀	0.05 μM Compound: Vinorelbine	Antiproliferative activity against human HEK293 cells assessed as growth inhibition measured for 48 hrs by MTT assay Antiproliferative activity against human HEK293 cells assessed as growth inhibition measured for 48 hrs by MTT assay	[PMID: 38833507]
HEK293	IC₅₀	15.9 nM Compound: VN	Antiproliferative activity against human HEK293 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human HEK293 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
HeLa	IC₅₀	0.026 μM Compound: 1e, AVLB	Cytotoxicity against human HeLa cells after 72 hrs by SRB assay Cytotoxicity against human HeLa cells after 72 hrs by SRB assay	[PMID: 17544278]
HeLa	IC₅₀	26.9 nM Compound: 1a	Cytotoxicity against human HeLa cells after 72 hrs by SRB assay Cytotoxicity against human HeLa cells after 72 hrs by SRB assay	[PMID: 18771244]
HeLa	GI₅₀	2.7 nM Compound: 3	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 19147348]
HeLa	IC₅₀	0.027 μM Compound: 1e	Cytotoxicity against human HeLa cells by sulforhodamine B assay Cytotoxicity against human HeLa cells by sulforhodamine B assay	[PMID: 19499938]
HeLa	IC₅₀	27 nM Compound: 1f, AVBL	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 22115594]
HeLa	IC₅₀	9 nM Compound: 1d	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 22525316]
HeLa	IC₅₀	0.066 μM Compound: Vinorelbine	Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay	[PMID: 29624387]
HeLa	IC₅₀	0.3 nM Compound: VN	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
HepG2	IC₅₀	23.12 μM Compound: Vinorelbine	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 26420067]
HepG2	IC₅₀	0.11 μM Compound: Vinorelbine	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32473523]
HL-60	IC₅₀	<0.06 μM Compound: vinorelbine	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 20462230]
HL-60	IC₅₀	<0.06 μmol Compound: vinorelbine	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 20462230]
HL-60	IC₅₀	11.47 μM Compound: Vinorelbine	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 26420067]
HT-1080	IC₅₀	0.1 nM Compound: VN	Antiproliferative activity against human HT-1080 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human HT-1080 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
HT-29	IC₅₀	11.9 nM Compound: Vinorelbine	Antiproliferative activity against human HT-29 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human HT-29 cells after 72 hrs by sulforhodamine B assay	[PMID: 21480626]
HUVEC	IC₅₀	2 nM Compound: 7, VLN	Cytotoxicity against HUVEC after 72 hrs by resazurin assay Cytotoxicity against HUVEC after 72 hrs by resazurin assay	[PMID: 23822556]
K562	IC₅₀	20 nM Compound: 7, VLN	Cytotoxicity against human K562 cells after 72 hrs by resazurin assay Cytotoxicity against human K562 cells after 72 hrs by resazurin assay	[PMID: 23822556]
K562	IC₅₀	3.5 nM Compound: 4, VLN	Antiproliferative activity against human K562 cells after 72 hrs Antiproliferative activity against human K562 cells after 72 hrs	[PMID: 24871162]
K562	IC₅₀	0.006 μM Compound: Vinorelbine	Cytotoxicity against human K562 cells after 72 hrs by resazurin-based fluorimetric assay Cytotoxicity against human K562 cells after 72 hrs by resazurin-based fluorimetric assay	[PMID: 24901800]
K562	IC₅₀	6 nM Compound: 3, VLN	Cytotoxicity against human K562 cells assessed as inhibition of cell proliferation after 72 hrs Cytotoxicity against human K562 cells assessed as inhibition of cell proliferation after 72 hrs	[PMID: 25804719]
K562	IC₅₀	0.003 μM Compound: 3; VLN	Cytotoxicity against human K562 cells incubated for 72 hrs by CellTiter 96 aqueous one solution reagent based assay Cytotoxicity against human K562 cells incubated for 72 hrs by CellTiter 96 aqueous one solution reagent based assay	[PMID: 27753480]
K562	IC₅₀	0.003 μmol Compound: 3; VLN	Cytotoxicity against human K562 cells incubated for 72 hrs by CellTiter 96 aqueous one solution reagent based assay Cytotoxicity against human K562 cells incubated for 72 hrs by CellTiter 96 aqueous one solution reagent based assay	[PMID: 27753480]
K-562R	IC₅₀	0.41 μM Compound: 3; VLN	Cytotoxicity against doxorubicin-resistant human K562R cells incubated for 72 hrs by CellTiter 96 aqueous one solution reagent based assay Cytotoxicity against doxorubicin-resistant human K562R cells incubated for 72 hrs by CellTiter 96 aqueous one solution reagent based assay	[PMID: 27753480]
K-562R	IC₅₀	0.41 μmol Compound: 3; VLN	Cytotoxicity against doxorubicin-resistant human K562R cells incubated for 72 hrs by CellTiter 96 aqueous one solution reagent based assay Cytotoxicity against doxorubicin-resistant human K562R cells incubated for 72 hrs by CellTiter 96 aqueous one solution reagent based assay	[PMID: 27753480]
KB	EC₅₀	6 nM Compound: Vinorelbine	Cell cycle arrest in human KB cells assessed as accumulation of cells at G2/M phase after 24 hrs by propidium iodide-based FACScan Cell cycle arrest in human KB cells assessed as accumulation of cells at G2/M phase after 24 hrs by propidium iodide-based FACScan	[PMID: 21480626]
L1210	IC₅₀	65 nM Compound: 22	Cytotoxicity against mouse L1210 cells assessed as growth inhibition after 72 hrs by phosphatase assay Cytotoxicity against mouse L1210 cells assessed as growth inhibition after 72 hrs by phosphatase assay	[PMID: 23252481]
MCF7	GI₅₀	2.4 nM Compound: 3	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 19147348]
MCF7	IC₅₀	0.07 μM Compound: vinorelbine	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 19743863]
MCF7	IC₅₀	17.2 μM Compound: vinorelbine	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 20462230]
MCF7	IC₅₀	17.2 μmol Compound: vinorelbine	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 20462230]
MCF7	IC₅₀	4 nM Compound: 4, VLN	Antiproliferative activity against human MCF7 cells after 72 hrs Antiproliferative activity against human MCF7 cells after 72 hrs	[PMID: 24871162]
MCF7	GI₅₀	3.9 nM Compound: Vinorelbine	Antiproliferative activity against human MCF7 cells assessed as growth inhibition measured for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as growth inhibition measured for 48 hrs by MTT assay	[PMID: 38833507]
MCF7	IC₅₀	0.8 nM Compound: VN	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
MDA-MB-231	GI₅₀	4.5 nM Compound: Vinorelbine	Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition measured for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition measured for 48 hrs by MTT assay	[PMID: 38833507]
MDA-MB-468	IC₅₀	0.1 nM Compound: VN	Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
MES-SA	IC₅₀	0.21 μM Compound: Vinorelbine	Cytotoxicity against human MES-SA cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MES-SA cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
MES-SA	IC₅₀	0.4 nM Compound: VN	Antiproliferative activity against human MES-SA cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human MES-SA cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
MES-SA/Dx5	IC₅₀	>32 μM Compound: Vinorelbine	Cytotoxicity against human MES-SA/Dx5 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MES-SA/Dx5 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
MIA PaCa-2	GI₅₀	0.8 nM Compound: Vinorelbine	Antiproliferative activity against human MIA PaCa-2 cells assessed as growth inhibition measured for 48 hrs by MTT assay Antiproliferative activity against human MIA PaCa-2 cells assessed as growth inhibition measured for 48 hrs by MTT assay	[PMID: 38833507]
NCI/ADR-RES	IC₅₀	5 μM Compound: VRB	Growth inhibition of doxorubicin-resistant human NCI-ADR-RES cells overexpressing P-glycoprotein after 96 hrs Growth inhibition of doxorubicin-resistant human NCI-ADR-RES cells overexpressing P-glycoprotein after 96 hrs	[PMID: 22044164]
NCI/ADR-RES	IC₅₀	5 μM Compound: VRB	Cytotoxicity against human NCI/ADR-RES cells assessed as growth inhibition by trypan blue exclusion assay Cytotoxicity against human NCI/ADR-RES cells assessed as growth inhibition by trypan blue exclusion assay	[PMID: 23214452]
NCI/ADR-RES	IC₅₀	5 μM Compound: VRB	Cytotoxicity against human NCI/ADR-RES cells assessed as growth inhibition after 96 hrs by Giemsa staining-based light microscopy Cytotoxicity against human NCI/ADR-RES cells assessed as growth inhibition after 96 hrs by Giemsa staining-based light microscopy	[PMID: 25025991]
NCI/ADR-RES	IC₅₀	5 μM Compound: VRB	Cytotoxicity against Pgp overexpressing human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against Pgp overexpressing human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26132075]
NCI/ADR-RES	IC₅₀	5 μM Compound: VRB	Growth inhibition of human NCI/ADR-RES cells after 96 hrs by trypan blue exclusion assay Growth inhibition of human NCI/ADR-RES cells after 96 hrs by trypan blue exclusion assay	[PMID: 29730191]
NCI/ADR-RES	IC₅₀	5 μM Compound: Vinorelbine	Antiproliferative activity against human NCI/ADR-RES cells assessed as inhibition of cell growth measured after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI/ADR-RES cells assessed as inhibition of cell growth measured after 48 hrs by sulforhodamine B assay	[PMID: 37902628]
NCI/ADR-RES	IC₅₀	3721 nM Compound: VNR	Reversal effect on P-gp-mediated multidrug resistance in human NCI/ADR-RES cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay Reversal effect on P-gp-mediated multidrug resistance in human NCI/ADR-RES cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay	[PMID: 38502936]
NCI-H1299	IC₅₀	0.23 μM Compound: Vinorelbine	Cytotoxicity against human NCI-H1299 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human NCI-H1299 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
NCI-H1975	IC₅₀	0.008 μM Compound: Vinorelbine	Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32473523]
NCI-H460	IC₅₀	43.7 nM Compound: Vinorelbine	Antiproliferative activity against human NCI-H460 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-H460 cells after 72 hrs by sulforhodamine B assay	[PMID: 21480626]
NCI-H661	IC₅₀	0.12 μM Compound: Vinorelbine	Cytotoxicity against human NCI-H661 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human NCI-H661 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
OVCAR-8	IC₅₀	300 nM Compound: VRB	Growth inhibition of human OVCAR8 cells overexpressing P-glycoprotein after 96 hrs Growth inhibition of human OVCAR8 cells overexpressing P-glycoprotein after 96 hrs	[PMID: 22044164]
OVCAR-8	IC₅₀	300 nM Compound: VRB	Cytotoxicity against human OVCAR8 cells assessed as growth inhibition by trypan blue exclusion assay Cytotoxicity against human OVCAR8 cells assessed as growth inhibition by trypan blue exclusion assay	[PMID: 23214452]
OVCAR-8	IC₅₀	300 nM Compound: VRB	Cytotoxicity against human OVCAR8 cells assessed as growth inhibition after 96 hrs by Giemsa staining-based light microscopy Cytotoxicity against human OVCAR8 cells assessed as growth inhibition after 96 hrs by Giemsa staining-based light microscopy	[PMID: 25025991]
OVCAR-8	IC₅₀	300 nM Compound: VRB	Cytotoxicity against human OVCAR8 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human OVCAR8 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26132075]
OVCAR-8	IC₅₀	300 nM Compound: VRB	Growth inhibition of human OVCAR8 cells after 96 hrs by trypan blue exclusion assay Growth inhibition of human OVCAR8 cells after 96 hrs by trypan blue exclusion assay	[PMID: 29730191]
PANC-1	GI₅₀	3 nM Compound: Vinorelbine	Antiproliferative activity against human PANC-1 cells assessed as growth inhibition measured for 48 hrs by MTT assay Antiproliferative activity against human PANC-1 cells assessed as growth inhibition measured for 48 hrs by MTT assay	[PMID: 38833507]
SK-OV-3	IC₅₀	26.7 nM Compound: Vinorelbine	Antiproliferative activity against human SKOV3 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human SKOV3 cells after 72 hrs by sulforhodamine B assay	[PMID: 21480626]
SMMC-7721	IC₅₀	4.7 μM Compound: vinorelbine	Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 20462230]
SMMC-7721	IC₅₀	4.7 μmol Compound: vinorelbine	Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 20462230]
SW480	IC₅₀	>40 μM Compound: vinorelbine	Cytotoxicity against human SW480 cells after 48 hrs by MTT assay Cytotoxicity against human SW480 cells after 48 hrs by MTT assay	[PMID: 20462230]
SW480	IC₅₀	>40 μmol Compound: vinorelbine	Cytotoxicity against human SW480 cells after 48 hrs by MTT assay Cytotoxicity against human SW480 cells after 48 hrs by MTT assay	[PMID: 20462230]
TERT-RPE1	IC₅₀	9.3 nM Compound: VN	Antiproliferative activity against human RPE-1 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay Antiproliferative activity against human RPE-1 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay	[PMID: 38959729]
U-87MG ATCC	IC₅₀	2 nM Compound: 7, VLN	Cytotoxicity against human U87MG cells after 72 hrs by resazurin assay Cytotoxicity against human U87MG cells after 72 hrs by resazurin assay	[PMID: 23822556]
U-87MG ATCC	IC₅₀	2 nM Compound: 4, VLN	Antiproliferative activity against human U87 cells after 72 hrs Antiproliferative activity against human U87 cells after 72 hrs	[PMID: 24871162]
U-87MG ATCC	IC₅₀	3.5 nM Compound: 3, VLN	Cytotoxicity against human U87 cells assessed as inhibition of cell proliferation after 72 hrs Cytotoxicity against human U87 cells assessed as inhibition of cell proliferation after 72 hrs	[PMID: 25804719]
U-937	GI₅₀	0.004 μM Compound: Vinorelbine	Antiproliferative activity against human U-937 cells assessed as growth inhibition measured for 48 hrs by MTT assay Antiproliferative activity against human U-937 cells assessed as growth inhibition measured for 48 hrs by MTT assay	[PMID: 38833507]

In Vitro

Vinorelbine (0.5-5 nM) inhibits cell proliferation by 50% (IC₅₀) at concentrations of 1.25 nM. At concentration of 8 nM vinorelbine, no cells are in anaphase^[1]. Vinorelbine time-dependently induces the p53 and p21^WAFI/CIP1 expression in androgen-dependent (AD) and- independent (AI) prostate cancer cell lines. Vinorelbine stimulates reporter genes in a concentration-dependent manner^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

After vinorelbine treatment, the first neutropenicepisode occurred after the first (4 dogs), second (1), or sixth(1) vinorelbine treatment in the dogs^[3]. Vinorelbine is tolerated at a weekly interval in tumor-bearing cats, with an MTD of 11.5 mg/m²^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Cell Viability Determination by MTT Colorimetric Assay

Chemical Information

CAS No. 71486-22-1
Molecular Weight 778.93
Formula C₄₅H₅₄N₄O₈
SMILES

CC[C@@]1(C=CCN2CC3)[C@@]2([H])[C@@]3(C(C=C([C@](C4=C5C(C=CC=C6)=C6N4)(C[C@@](C=C(CC)C7)([H])C[N@]7C5)C(OC)=O)C(OC)=C8)=C8N9C)[C@]9([H])[C@](C(OC)=O)(O)[C@@H]1OC(C)=O
Synonyms

KW-2307 base
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (24)

All Histological Imaging/StainingRT-PCRIn Vivo Efficacy StudyCell Proliferation/Viability AssayBio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Cell Mol Immunol

Arsenic trioxide elicits prophylactic and therapeutic immune responses against solid tumors by inducing necroptosis and ferroptosis. [Abstract]

2023 Jan;20(1):51-64. PMID: 36447031

Vinorelbine purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2023 Jan;20(1):51-64. [Abstract]

Comparison of drug (Epirubicin hydrochloride, EPI; Daunorubicin hydrochloride, DNR; Vinorelbine ditartrate, VNR; Oxaliplatin, OXA; Vincristine, VCR; Artemisinin, ART; Colchicine, COL) cytotoxicity to TC1 cells at the indicated doses and time points measured with CCK-8 assays. R.U. (Relative unit) was calculated from the average O.D. values in each condition as the indicator of cell viability (n = 3).
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 15;6(4):102053. PMID: 40187357
Sci Adv

Gain-of-function mutations in the catalytic domain of DOT1L promote lung cancer malignant phenotypes via the MAPK/ERK signaling pathway. [Abstract]

2023 Jun 2;9(22):eadc9273. PMID: 37256945

Vinorelbine purchased from MedChemExpress. Usage Cited in: Sci Adv. 2023 Jun 2;9(22):eadc9273. [Abstract]

CCK-8 assay data showing the sensitivity of NCI-H460-DOT1L-WT/R231Q cells to cisplatin, vinorelbine, and SGC0946. Cells were treated for 72 hours (Cisplatin and Vinorelbine (0.01-100 μM)) or 6 days (SGC0946). IC₅₀ values were calculated using SPSS V 21.0 software.

Vinorelbine purchased from MedChemExpress. Usage Cited in: Sci Adv. 2023 Jun 2;9(22):eadc9273. [Abstract]

CDX-bearing mice (n = 7 mice per group) were treated with vehicle [10% dimethyl sulfoxide (DMSO) + 40% polyethylene glycol 300 (PEG300) + 5% Tween 80 + 45% saline, five times per week], Cisplatin (3 mg/kg, twice per week), Vinorelbine (4 mg/kg, twice per week), or SGC0946 (20 mg/kg, five times per week) through intraperitoneal administration. The graphs show the tumor images and weights, with the tumor inhibition rate (TIR%). (TIR%) = (1 − average tumor weight after drug treatment/average tumor weight of vehicle control) × 100%.

Vinorelbine purchased from MedChemExpress. Usage Cited in: Sci Adv. 2023 Jun 2;9(22):eadc9273. [Abstract]

Synergistic effect of MAPK inhibition with Cisplatin or Vinorelbine on NCI-H460-DOT1L-R231Q cells after 72 hours of treatment.
Cell Death Dis

PMEPA1 modulates YAP1 nuclear translocation to disrupt EMT subtypes and promote metastasis in Biliary tract cancer. [Abstract]

2026 Apr 3;17(1):449. PMID: 41932868
EBioMedicine

Transcriptomics based multi-dimensional characterization and drug screen in esophageal squamous cell carcinoma. [Abstract]

2021 Aug:70:103510. PMID: 34365093

Vinorelbine purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2021 Aug:70:103510. [Abstract]

We compared the actual drug response data of the aforementioned S1/S2 specific agents between S1- and S2-like cells and found that S1-like cell lines were more sensitive to TG-101348, while S2-like cell lines (ESCC cancer cell lines) were more sensitive to Vinorelbine (48 h) and ZM-447439.
Microsyst Nanoeng

Double emulsion-pretreated microwell culture for the in vitro production of multicellular spheroids and their in situ analysis. [Abstract]

2021 May 24:7:38. PMID: 34567752
Acta Pharmacol Sin

A novel FAK-degrading PROTAC molecule exhibited both anti-tumor activities and efficient MDR reversal effects. [Abstract]

2024 Oct;45(10):2174-2185. PMID: 38844788
Anal Chem

2026 Aug 4;98(30):22201-22214. PMID: 42473352
Biochem Pharmacol

Precision-engineered reporter cell lines reveal ABCG2 regulation in live lung cancer cells. [Abstract]

2020 May;175:113865. PMID: 32142727
Microb Cell Fact

Lactobacillus gasseri LGV03-derived indole-3-lactic acid ameliorates immune response by activating aryl hydrocarbon receptor. [Abstract]

2025 Jan 30;24(1):34. PMID: 39885499

Vinorelbine purchased from MedChemExpress. Usage Cited in: Microb Cell Fact. 2025 Jan 30;24(1):34. [Abstract]

L. gasseri LGV03 inhibits Vinorelbine (200 μg/mL, 96 h)-induced macrophage reduction in zebrafish model Tg (mpeg-EGFP) (right). Number of macrophages in zebrafish after treatment of Vinorelbine and L. gasseri LGV03 (left).

Vinorelbine purchased from MedChemExpress. Usage Cited in: Microb Cell Fact. 2025 Jan 30;24(1):34. [Abstract]

mRNA gene expression of cytokines TNF-α, TNF-β and IFN-α in zebrafish (Vinorelbine, 200 μg/mL, 96 h).
Int J Cancer

Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients. [Abstract]

2024 Jul 15;155(2):324-338. PMID: 38533706
Cancers (Basel)

miR-92b-3p Regulates Cell Cycle and Apoptosis by Targeting CDKN1C, Thereby Affecting the Sensitivity of Colorectal Cancer Cells to Chemotherapeutic Drugs. [Abstract]

2021 Jul 2;13(13):3323. PMID: 34283053
J Cell Mol Med

Inactivation of CDK12 Enhances Mitochondrial Efficiency to Suppress DNA Damage. [Abstract]

2026 Apr;30(7):e71101. PMID: 41896195
Adv Ther

2024 Jul 18.
iScience

Multiomic characterization and drug testing establish circulating tumor cells as an ex vivo tool for personalized medicine. [Abstract]

2022 Sep 6;25(10):105081. PMID: 36204272
J Bone Oncol

Identification of GPC3 mutation and upregulation in a multidrug resistant osteosarcoma and its spheroids as therapeutic target. [Abstract]

2021 Sep 20:30:100391. PMID: 34611509
Transl Lung Cancer Res

Construction of a lung cancer 3D culture model based on alginate/gelatin micro-beads for drug evaluation. [Abstract]

2024 Oct 31;13(10):2698-2712. PMID: 39507032
Am J Cancer Res

Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1. [Abstract]

2021 Apr 15;11(4):1428-1445. PMID: 33948366
Biochem Biophys Res Commun

Eribulin mesylate-induced c-Fos upregulation enhances cell survival in breast cancer cell lines. [Abstract]

2020 May 21;526(1):154-157. PMID: 32201082
Int J Clin Pract

2026 Apr 25;2026(1):6800480.
bioRxiv

2026 Jan 9.
Res Sq

2026 Jan 9.
bioRxiv

MCL1 may not mediate chemoresistance. [Abstract]

2025 Aug 27:2025.08.22.671824. PMID: 40909578
Res Sq

Novel mixed cancer-cell models designed to capture inter-patient tumor heterogeneity for accurate evaluation of drug combinations. [Abstract]

2025 May 16:rs.3.rs-6590535. PMID: 40470249

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (301 KB)
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Ngan VK, et al. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol. 2001 Jul;60(1):225-32. [Content Brief]

[2]. Liu XM, et al. Unique induction of p21(WAF1/CIP1)expression by vinorelbine in androgen-independent prostate cancer cells. Br J Cancer. 2003 Oct 20;89(8):1566-73. [Content Brief]

[3]. Poirier VJ, et al. Toxicity, dosage, and efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia. J Vet Intern Med. 2004 Jul-Aug;18(4):536-9. [Content Brief]

[4]. Pierro JA, et al. Phase I clinical trial of vinorelbine in tumor-bearing cats. J Vet Intern Med. 2013 Jul-Aug;27(4):943-8. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity: